(Q53179258)

12 May 2018

title

Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma. (English)

1 reference

12 May 2018

author name string

Nengwang Yu

1

1 reference

12 May 2018

Shuai Fu

2

1 reference

12 May 2018

Zhonghua Xu

3

1 reference

12 May 2018

Yi Liu

4

1 reference

12 May 2018

Junwen Hao

5

1 reference

12 May 2018

Aimin Zhang

6

1 reference

12 May 2018

Baocheng Wang

7

1 reference

12 May 2018

language of work or name

English

0 references

publication date

18 August 2015

1 reference

12 May 2018

International Journal of Cancer

published in

1 reference

12 May 2018

volume

138

1 reference

12 May 2018

issue

2

1 reference

12 May 2018

page(s)

451-462

1 reference

12 May 2018

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review

cites work

1 reference

Adjuvant therapy for locally advanced renal cell cancer: a systematic review with meta-analysis

21 January 2018

1 reference

High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.

21 January 2018

1 reference

Targeted therapeutic strategies for the management of renal cell carcinoma

21 January 2018

1 reference

Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm

21 January 2018

1 reference

Emerging immunotherapies for renal cell carcinoma

21 January 2018

1 reference

Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study

21 January 2018

1 reference

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

21 January 2018

1 reference

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients

21 January 2018

1 reference

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

21 January 2018

1 reference

Deciphering and reversing tumor immune suppression.

21 January 2018

1 reference

Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy

21 January 2018

1 reference

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination

21 January 2018

1 reference

Combining immunotherapy and targeted therapies in cancer treatment

21 January 2018

1 reference

Advances in targeting cell surface signalling molecules for immune modulation

21 January 2018

1 reference

Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination.

21 January 2018

1 reference

PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.

21 January 2018

1 reference

Agonist antibodies to TNFR molecules that costimulate T and NK cells

21 January 2018

1 reference

TNF/TNFR family members in costimulation of T cell responses

21 January 2018

1 reference

Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.

21 January 2018

1 reference

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

21 January 2018

1 reference

Pharmacological modulation of GITRL/GITR system: therapeutic perspectives.

21 January 2018

1 reference

A murine renal cell carcinoma

21 January 2018

1 reference

Isolation and Metastatic Properties of Detachment Variants of 816 Melanoma Cells 2

21 January 2018

1 reference

mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment

21 January 2018

1 reference

Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells

21 January 2018

1 reference

Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice

21 January 2018

1 reference

Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained

21 January 2018

1 reference

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

21 January 2018

1 reference

Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy

21 January 2018

1 reference

Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis

21 January 2018

1 reference

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

Macrophages, innate immunity and cancer: balance, tolerance, and diversity

21 January 2018

1 reference

Glucocorticoid-induced tumour necrosis factor receptor-related protein-mediated macrophage stimulation may induce cellular adhesion and cytokine expression in rheumatoid arthritis

21 January 2018

1 reference

Glucocorticoid-induced tumour necrosis factor receptor family related protein (GITR) mediates inflammatory activation of macrophages that can destabilize atherosclerotic plaques.

21 January 2018

1 reference

Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy.

21 January 2018

1 reference

Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor.

21 January 2018

1 reference

The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE₂ in murine macrophages

21 January 2018

1 reference

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

21 January 2018

1 reference

Altered macrophage differentiation and immune dysfunction in tumor development

21 January 2018

1 reference

Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies

21 January 2018

1 reference

Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.29713

1 reference

12 May 2018

PubMed ID

26239999

1 reference

12 May 2018